Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
Identifieur interne : 000973 ( PubMed/Corpus ); précédent : 000972; suivant : 000974Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
Auteurs : Jean-Hugues Salmon ; Jeanne-Marie Perotin ; Jacques Morel ; Moustapha Dramé ; Alain Cantagrel ; Liana Euller Ziegler ; Philippe Ravaud ; Jean Sibilia ; Isabelle Pane ; Xavier Mariette ; Jacques-Eric GottenbergSource :
- Rheumatology (Oxford, England) [ 1462-0332 ] ; 2018.
English descriptors
- KwdEn :
- Abatacept (adverse effects), Adult, Aged, Anaphylaxis (chemically induced), Anaphylaxis (epidemiology), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (adverse effects), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (drug therapy), Arthritis, Rheumatoid (immunology), Drug Eruptions (epidemiology), Drug Eruptions (etiology), Female, Humans, Hypertension (chemically induced), Hypertension (epidemiology), Infusions, Intravenous, Logistic Models, Male, Middle Aged, Multivariate Analysis, Peptides, Cyclic (immunology), Pharyngitis (chemically induced), Pharyngitis (epidemiology), Registries, Risk Factors, Rituximab (adverse effects), Severity of Illness Index.
- MESH :
- chemical , adverse effects : Abatacept, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Rituximab.
- chemically induced : Anaphylaxis, Hypertension, Pharyngitis.
- drug therapy : Arthritis, Rheumatoid.
- epidemiology : Anaphylaxis, Drug Eruptions, Hypertension, Pharyngitis.
- etiology : Drug Eruptions.
- immunology : Arthritis, Rheumatoid, Peptides, Cyclic.
- chemical , therapeutic use : Antirheumatic Agents.
- Adult, Aged, Female, Humans, Infusions, Intravenous, Logistic Models, Male, Middle Aged, Multivariate Analysis, Registries, Risk Factors, Severity of Illness Index.
Abstract
The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics.
DOI: 10.1093/rheumatology/kex403
PubMed: 29069471
Links to Exploration step
pubmed:29069471Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.</title><author><name sortKey="Salmon, Jean Hugues" sort="Salmon, Jean Hugues" uniqKey="Salmon J" first="Jean-Hugues" last="Salmon">Jean-Hugues Salmon</name><affiliation><nlm:affiliation>Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims.</nlm:affiliation></affiliation></author><author><name sortKey="Perotin, Jeanne Marie" sort="Perotin, Jeanne Marie" uniqKey="Perotin J" first="Jeanne-Marie" last="Perotin">Jeanne-Marie Perotin</name><affiliation><nlm:affiliation>Department of Respiratory Diseases and Allergology, Maison Blanche Hospital, Reims University Hospitals.</nlm:affiliation></affiliation></author><author><name sortKey="Morel, Jacques" sort="Morel, Jacques" uniqKey="Morel J" first="Jacques" last="Morel">Jacques Morel</name><affiliation><nlm:affiliation>Department of Rheumatology, University of Montpellier and Teaching Hospital Lapeyronie, Montpellier.</nlm:affiliation></affiliation></author><author><name sortKey="Drame, Moustapha" sort="Drame, Moustapha" uniqKey="Drame M" first="Moustapha" last="Dramé">Moustapha Dramé</name><affiliation><nlm:affiliation>Faculty of Medicine, University of Reims Champagne-Ardenne, EA, 3797.</nlm:affiliation></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation><nlm:affiliation>Rheumatology Department, Purpan Hospital, Paul Sabatier University, Toulouse.</nlm:affiliation></affiliation></author><author><name sortKey="Ziegler, Liana Euller" sort="Ziegler, Liana Euller" uniqKey="Ziegler L" first="Liana Euller" last="Ziegler">Liana Euller Ziegler</name><affiliation><nlm:affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</nlm:affiliation></affiliation></author><author><name sortKey="Ravaud, Philippe" sort="Ravaud, Philippe" uniqKey="Ravaud P" first="Philippe" last="Ravaud">Philippe Ravaud</name><affiliation><nlm:affiliation>Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris.</nlm:affiliation></affiliation></author><author><name sortKey="Sibilia, Jean" sort="Sibilia, Jean" uniqKey="Sibilia J" first="Jean" last="Sibilia">Jean Sibilia</name><affiliation><nlm:affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</nlm:affiliation></affiliation></author><author><name sortKey="Pane, Isabelle" sort="Pane, Isabelle" uniqKey="Pane I" first="Isabelle" last="Pane">Isabelle Pane</name><affiliation><nlm:affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</nlm:affiliation></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation><nlm:affiliation>Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre.</nlm:affiliation></affiliation></author><author><name sortKey="Gottenberg, Jacques Eric" sort="Gottenberg, Jacques Eric" uniqKey="Gottenberg J" first="Jacques-Eric" last="Gottenberg">Jacques-Eric Gottenberg</name><affiliation><nlm:affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29069471</idno><idno type="pmid">29069471</idno><idno type="doi">10.1093/rheumatology/kex403</idno><idno type="wicri:Area/PubMed/Corpus">000973</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000973</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.</title><author><name sortKey="Salmon, Jean Hugues" sort="Salmon, Jean Hugues" uniqKey="Salmon J" first="Jean-Hugues" last="Salmon">Jean-Hugues Salmon</name><affiliation><nlm:affiliation>Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims.</nlm:affiliation></affiliation></author><author><name sortKey="Perotin, Jeanne Marie" sort="Perotin, Jeanne Marie" uniqKey="Perotin J" first="Jeanne-Marie" last="Perotin">Jeanne-Marie Perotin</name><affiliation><nlm:affiliation>Department of Respiratory Diseases and Allergology, Maison Blanche Hospital, Reims University Hospitals.</nlm:affiliation></affiliation></author><author><name sortKey="Morel, Jacques" sort="Morel, Jacques" uniqKey="Morel J" first="Jacques" last="Morel">Jacques Morel</name><affiliation><nlm:affiliation>Department of Rheumatology, University of Montpellier and Teaching Hospital Lapeyronie, Montpellier.</nlm:affiliation></affiliation></author><author><name sortKey="Drame, Moustapha" sort="Drame, Moustapha" uniqKey="Drame M" first="Moustapha" last="Dramé">Moustapha Dramé</name><affiliation><nlm:affiliation>Faculty of Medicine, University of Reims Champagne-Ardenne, EA, 3797.</nlm:affiliation></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation><nlm:affiliation>Rheumatology Department, Purpan Hospital, Paul Sabatier University, Toulouse.</nlm:affiliation></affiliation></author><author><name sortKey="Ziegler, Liana Euller" sort="Ziegler, Liana Euller" uniqKey="Ziegler L" first="Liana Euller" last="Ziegler">Liana Euller Ziegler</name><affiliation><nlm:affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</nlm:affiliation></affiliation></author><author><name sortKey="Ravaud, Philippe" sort="Ravaud, Philippe" uniqKey="Ravaud P" first="Philippe" last="Ravaud">Philippe Ravaud</name><affiliation><nlm:affiliation>Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris.</nlm:affiliation></affiliation></author><author><name sortKey="Sibilia, Jean" sort="Sibilia, Jean" uniqKey="Sibilia J" first="Jean" last="Sibilia">Jean Sibilia</name><affiliation><nlm:affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</nlm:affiliation></affiliation></author><author><name sortKey="Pane, Isabelle" sort="Pane, Isabelle" uniqKey="Pane I" first="Isabelle" last="Pane">Isabelle Pane</name><affiliation><nlm:affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</nlm:affiliation></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation><nlm:affiliation>Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre.</nlm:affiliation></affiliation></author><author><name sortKey="Gottenberg, Jacques Eric" sort="Gottenberg, Jacques Eric" uniqKey="Gottenberg J" first="Jacques-Eric" last="Gottenberg">Jacques-Eric Gottenberg</name><affiliation><nlm:affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Rheumatology (Oxford, England)</title><idno type="eISSN">1462-0332</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abatacept (adverse effects)</term><term>Adult</term><term>Aged</term><term>Anaphylaxis (chemically induced)</term><term>Anaphylaxis (epidemiology)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (adverse effects)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthritis, Rheumatoid (immunology)</term><term>Drug Eruptions (epidemiology)</term><term>Drug Eruptions (etiology)</term><term>Female</term><term>Humans</term><term>Hypertension (chemically induced)</term><term>Hypertension (epidemiology)</term><term>Infusions, Intravenous</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Peptides, Cyclic (immunology)</term><term>Pharyngitis (chemically induced)</term><term>Pharyngitis (epidemiology)</term><term>Registries</term><term>Risk Factors</term><term>Rituximab (adverse effects)</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abatacept</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Anaphylaxis</term><term>Hypertension</term><term>Pharyngitis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anaphylaxis</term><term>Drug Eruptions</term><term>Hypertension</term><term>Pharyngitis</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug Eruptions</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Peptides, Cyclic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Registries</term><term>Risk Factors</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29069471</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>01</Month><Day>01</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.</ArticleTitle><Pagination><MedlinePgn>134-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/kex403</ELocationID><Abstract><AbstractText Label="Objective">The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics.</AbstractText><AbstractText Label="Methods">We analysed data from three independent prospective registers, namely autoimmunity and rituximab, Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab), promoted by the French Society of Rheumatology and including patients with RA. SIRRs were defined by an occurrence during or within 24 h of an infusion and requiring discontinuation of treatment. Characteristics of patients with SIRRs were extracted from the electronic database.</AbstractText><AbstractText Label="Results">Among the 4145 patients, SIRRs occurred in 100 patients: 56 patients with the rituximab cohort (2.8% or 0.7/100 patient-years), 15 with the abatacept cohort (1.5% or 0.6/100 patient-years) and 29 with tocilizumab (1.9% or 1/100 patient-years). No fatal SIRR occurred. A previous mild infusion reaction to non-TNF-targeted biologics was observed in a quarter of patients with SIRRs. After pooled multivariate analysis, positive anti-CCP was associated with a higher risk of SIRR (odds ratio = 2.5; 95% CI: 1.01, 6.17). Absence of concomitant treatment with a synthetic DMARD tended to be associated with a higher risk of SIRR (odds ratio = 1.67; 95% CI: 1.00, 2.86).</AbstractText><AbstractText Label="Conclusion">In daily practice, SIRRs are slightly more frequent than in clinical trials and rarely life threatening. In common practice, serological status (anti-CCP positivity) and absence of concomitant treatment with a synthetic DMARD increase the risk of SIRR.</AbstractText><CopyrightInformation>© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>Jean-Hugues</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Maison Blanche Hospital, Reims University Hospitals, Reims.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Reims Champagne-Ardenne, EA, 3797.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perotin</LastName><ForeName>Jeanne-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Diseases and Allergology, Maison Blanche Hospital, Reims University Hospitals.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM UMRS 903, University of Reims Champagne-Ardenne, Reims.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morel</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University of Montpellier and Teaching Hospital Lapeyronie, Montpellier.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dramé</LastName><ForeName>Moustapha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Reims Champagne-Ardenne, EA, 3797.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research and Innovation, Robert Debré Hospital, Reims University Hospitals, Reims.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantagrel</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Purpan Hospital, Paul Sabatier University, Toulouse.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Liana Euller</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravaud</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibilia</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, L'Archet Hospital, Nice.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pane</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM UMRS_1109, Université de Strasbourg, Strasbourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariette</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1184, IMVA: Center of Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottenberg</LastName><ForeName>Jacques-Eric</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Rheumatology Department, National Center for Rare Systemic Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Université de Strasbourg, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Society of Rheumatology</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487763">cyclic citrullinated peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>7D0YB67S97</RegistryNumber><NameOfSubstance UI="D000069594">Abatacept</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069594" MajorTopicYN="N">Abatacept</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000707" MajorTopicYN="N">Anaphylaxis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003875" MajorTopicYN="N">Drug Eruptions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010612" MajorTopicYN="N">Pharyngitis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">biological DMARDs</Keyword><Keyword MajorTopicYN="Y">infusion-related reactions</Keyword><Keyword MajorTopicYN="Y">registries</Keyword><Keyword MajorTopicYN="Y">rheumatoid arthritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29069471</ArticleId><ArticleId IdType="pii">4562462</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/kex403</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000973 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000973 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29069471
|texte= Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29069471" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |